COMP <GO>
KYMR vs TECH // PIOTROSKI F-SCORE QUALITY
Kymera Therapeutics Inc. (NASDAQ) VS. Bio-Techne Corp (NASDAQ) • 15-METRIC TALLY: KYMR 5
— TECH 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: TECH
LAST: $126.63 (+3.29%) • MKT CAP: $10.81B
piotroski-score
4/9
LAST: $72.66 (-0.07%) • MKT CAP: $11.39B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. TECH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | TECH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 64.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 3.40% | -24.80 | TECH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 91.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 2.25% | -4.55 | TECH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 8.40% | -68.40 | TECH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.00% | +62.00 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 5.20% | -21.90 | TECH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.44% | -0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 7.12 | +18.88 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 8/9 | -4.00 | TECH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 56.1 | +9.90 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.88 | +0.07 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 140.0x | -109.60 | KYMR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.81B | $11.39B | -$583.8M | TECH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | TECH REV | KYMR GROSS % | TECH GROSS % | KYMR FCF | TECH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $1.22B | 0.0% | 64.8% | -$234.3M | $256.6M |
| FY 2024 | $47.1M | $1.16B | 0.0% | 66.4% | -$207.3M | $236.1M |
| FY 2023 | $78.6M | $1.14B | — | — | -$106.4M | $203.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
TECH // BETA 0.88